Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

Rodney P. Rocconi,Sharad A. Ghamande,Minal A. Barve,Erin E. Stevens,Phylicia Aaron,Laura Stanbery,Ernest Bognar,Luisa Manning,John Nemunaitis,David M. OMalley,Thomas J. Herzog,Bradley J. Monk,Robert L. Coleman

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

2021

Rodney P. Rocconi
Sharad A. Ghamande
Minal A. Barve
Erin E. Stevens
Phylicia Aaron
Laura Stanbery
Ernest Bognar
Luisa Manning
John Nemunaitis
David M. OMalley
Thomas J. Herzog
Bradley J. Monk
Robert L. Coleman

5502Background: In the VITAL (NCT02346747) trial, maintenance therapy with Vigil, an autologous tumor cell vaccine transfected with a DNA plasmid encoding GMCSF and bi-shRNA-furin for TGFβ expressi...

Keywords:

Medicine
Internal medicine
Oncology
Transfection
newly diagnosed
Vigil
Autologous Tumor Cell Vaccine
Maintenance therapy
Immunotherapy
Plasmid
Homologous recombination

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations